Journal
VIRUSES-BASEL
Volume 7, Issue 8, Pages 4529-4562Publisher
MDPI
DOI: 10.3390/v7082832
Keywords
enterovirus; human parechovirus; replication; antiviral; small molecules; inhibitor
Categories
Funding
- European Union FP7: Marie Curie IAPP AIROPico [612308]
- European Union FP7: Marie Curie Initial Training Network EUVIRNA [264286]
- European Union FP7: Large Scale Collaborative Project SILVER [260644]
- Netherlands Organisation for Scientific Research (NWO) [ALW-820.02.018, VICI-91812628]
- Crucell
Ask authors/readers for more resources
The Enterovirus (EV) and Parechovirus genera of the picornavirus family include many important human pathogens, including poliovirus, rhinovirus, EV-A71, EV-D68, and human parechoviruses (HPeV). They cause a wide variety of diseases, ranging from a simple common cold to life-threatening diseases such as encephalitis and myocarditis. At the moment, no antiviral therapy is available against these viruses and it is not feasible to develop vaccines against all EVs and HPeVs due to the great number of serotypes. Therefore, a lot of effort is being invested in the development of antiviral drugs. Both viral proteins and host proteins essential for virus replication can be used as targets for virus inhibitors. As such, a good understanding of the complex process of virus replication is pivotal in the design of antiviral strategies goes hand in hand with a good understanding of the complex process of virus replication. In this review, we will give an overview of the current state of knowledge of EV and HPeV replication and how this can be inhibited by small-molecule inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available